News und Analysen
1 Reason to Buy UnitedHealth Group Stock Before Oct. 28
Shares of America's largest health insurer, UnitedHealth Group, have been on a relatively wild ride. After hitting a peak in April, the stock fell by more than half.
Shares of UnitedHealth Group
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer (NYSE: PFE) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news. But Pfizer's price rebound
3 Dividend Stocks to Double Up On Right Now
If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many
This Artificial Intelligence (AI) Stock Is Quietly Outperforming Nvidia in 2025
Nvidia is arguably the king of Wall Street these days. As the maker of high-performing graphics processing units (GPUs) that power artificial intelligence (AI) programs and large language models
Summit Financial Loads Up FTSM With Over 334,000 Shares in Q3
Summit Financial Wealth Advisors, LLC initiated a new position in First Trust Enhanced Short Maturity ETF (NASDAQ:FTSM), acquiring approximately $20.03 million in shares as of Q3 2025, according to
St Louis Financial Loads Up on UnitedHealth Group (UNH) With a 12,500 Share Purchase
According to an SEC filing dated October 2, 2025, St. Louis Financial Planners Asset Management, LLC initiated a new stake in UnitedHealth Group (NYSE:UNH), purchasing 12,542 shares during the third
Massive News for AMD Stock Investors
In this video, I will discuss recent updates regarding Advanced Micro Devices (NASDAQ: AMD) and OpenAI. Watch the short video to learn more, consider subscribing, and click the special offer link
Great News for Pfizer Stock Investors
Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products.
*Stock prices used were the afternoon prices of Oct. 3, 2025. The video was published on Oct. 5
3 Reasons to Buy Pfizer Stock Now
Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The
2 Beaten-Down Stocks Primed for a Comeback
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good
Could Buying Rivian Stock Today Set You Up for Life?
At a time when many automakers are pulling back from electric vehicles (EVs), Rivian Automotive (NASDAQ: RIVN) is embracing its branding as an EV-only company. It just broke ground on a new factory
1 Monster Stock in the Making to Buy and Hold
Even in hindsight, it would have been difficult to predict Summit Therapeutics' (NASDAQ: SMMT) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500%
Can Pfizer's Stock Break This Disappointing Streak?
Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.
It has developed many medicines over the years
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Shares of Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly
2 Surefire Dividend Stocks to Buy for the Long Haul
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a
4 Reasons to Buy Amgen Stock Right Now
Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (NASDAQ: AMGN) started the year
Why Genmab Stock Popped on Friday
Before the market open on the last trading day of the week, two analysts tracking Genmab (NASDAQ: GMAB) stock felt compelled to raise their price targets on the biotech. This double-barreled blast
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.
According to a Securities and
1 Reason to Buy UnitedHealth Group Stock Before Oct. 28
Health insurer UnitedHealth Group (NYSE: UNH) reports its third-quarter earnings results later this month, on Oct. 28. It could be a pivotal report for the company, which indicates whether the
St. Louis Financial Sells $3.3 Million in AT&T Stock With Next Earnings on Deck
St. Louis Financial Planners Asset Management, LLC disclosed in a Thursday filing with the SEC that it sold shares of AT&T worth an estimated $3.3 million in the third quarter.
According to a
Why Shares of Eli Lilly Soared This Week
Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical
Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?
The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
Explore the exciting world of Zoetis (NYSE: ZTS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
Why Did AngioDynamics Stock Pop Today?
AngioDynamics (NASDAQ: ANGO) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.
Heading into the report, analysts forecast AngioDynamics would lose


